A new anti-obesity medication from Lilly, a weekly injection of retatrutide, has shown significant promise in clinical trials. The drug was found to reduce moderate to severe sleep apnea by 60.6% in obese adults.

Una ensayo reveló que una inyección semanal de retatrutide reducía el problema de sueño de moderado a grave en 60.6% en adultos con obesidad